Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Stoke Therapeutics (NASDAQ:STOK) was given a new $50.00 price target on by analysts at UBS Group AG.
Stoke Therapeutics (NASDAQ:STOK) had its price target raised by analysts at HC Wainwright from $35.00 to $50.00. They now have a "buy" rating on the stock.
Stoke Therapeutics' Chief Medical Officer Sold Over 5,000 Shares in the Company. Should Shareholders Sell? [Yahoo! Finance]
Is New Neurology Data And Partnerships Altering The Investment Case For Biogen (BIIB)? [Yahoo! Finance]